Background: Heart-rate (HR) variability is an important predictor of mortality in patients with heart disease. We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes.
Patients and Methods: Thirteen patients with chronic atrial fibrillation associated with bra dycardia episodes (minimal HR <40/min and/or pauses, ie, episodes with an RR interval > 2.5 sec) received cilostazol (100 or 200 mg/day) orally for at least 2 months and 24-hour Holter electrocardiography was performed before and after the start of cilostazol administration.
Results: Minimal HR was significantly increased, by an average of 14 beats/min (bpm), at 3.3 ± 0.8 weeks (mean ± SD) after the start of cilostazol treatment. The number of pauses was significantly decreased. As a consequence, mean HR was increased by an average of 18 bpm. Maximal HR was also increased by an average of 19 bpm. The circadian variation of the HR, determined by cosine fitting, was not changed by cilostazol treatment. The time-domain HR variabilities, ie, the SD of the mean RR interval and the SD of the 5-minute mean RR intervals, were also unchanged. New York Heart Association functional class was signifi cantly improved and the plasma atrial natriuretic polypeptide level was significantly de creased after the initiation of cilostazol treatment.
Conclusion: Cilostazol improves the slow HR episodes associated with chronic atrial fibril lation and maintains the HR circadian variation and time-domain variability, indicating that cilostazol has therapeutic utility for the treatment of the slow HR associated with chronic atrial fibrillation.
Rawles JMWhat is meant by a "controlled ventricular rate in atrial fibrillation." Br Heart J63:157, 1990
2.
TheStroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, 1: Clinical features of patients at risk. Ann Intern Med116:1, 1992
3.
Raider EACircadian fluctuations in ventricular response to atrial fibrillation. Am J Cardiol66:1013, 1990
4.
Toivonen L., Kadaish A., Kou W., et al. Determinants of the ventricular rate during atrial fibrillation . J Am Coll Cardiol16:1194, 1990
5.
Umekawa H., Tanaka T., Kimura Y., et al. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol33:3339, 1984
6.
Kamiya T., Sakaguchi S.Hemodynamic effects of the antithrombotic drug Cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung35:1201, 1985
7.
Kawamura K., Fujita S., Tani T., et al. Effects of Cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency. Arzneimittelforschung35:1154, 1985
8.
Kauffman RF, Crowe VG, Utterback BG, et al. LY 195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol30:609, 1986
9.
Weishaar RE, Quade MM, Schenden JA, et al. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics. J Cyclic Nucleotide Protein Phosphorylation Res10:551, 1985
10.
Naccarelli GV , Goldstein RAElectrophysiology of phosphodiesterase inhibitors . Am J Cardiol63:35A, 1989
11.
Atarashi H. , Endoh Y., Saitoh H., et al. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol31:534, 1998
12.
Malik M.Heart rate variability. Curr Opin Cardiol13:36, 1998
13.
Frey B., Heinz G., Binder T., et al. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. Am Heart J129:58, 1995
14.
Stein KM, Borer JS, Hochreiter C., et al. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. Am J Cardiol74:906, 1994
15.
Stein KM, Borer JS, Hochreiter C., et al. Prognostic value and physiological correlates of heart rate variability in chronic severe mitral regurgitation. Circulation88:127, 1993
16.
World Medical Association Declaration of Helsinki.Recommendations guiding physicians in biomedical research involving human subjects. JAMA277:925, 1997
17.
Billette J. , Nadeau RA, Roberge F.Relation between the minimum RR interval during atrial fibrillation and the functional refractory period of the AV junction . Cardiovas Res8:347, 1974
18.
Anan T., Sunagawa K., Araki H., et al. Arrhythmia analysis by successive RR plotting. J Electrocardiol23:243, 1990
19.
Feigenbaum H.Echocardiographic findings with altered electrical activation. In Feigenbaum H (ed.) Echocardiography. Lea & Ferbiger, Philadelphia, pp. 216-238, 1994
20.
Hashida S., Ishikawa E.Novel and ultrasensitive noncompetitive enzyme immunoassay (hetero-two-site complex transfer enzyme immunoassay) for alpha-human atrial natriuretic peptide . J Clin Lab Anal6:201, 1992
21.
Akiyama H., Kudo S., Shimizu T.The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung35:1133, 1985
22.
Fricke GR, Mattern H., Fricke KJOptimization of the regular frequency of the heart in atrial fibrillation in relation to the cardiac output. Resuscitation8:69, 1980
23.
Herbert WHCardiac output and the varying R-R interval of atrial fibrillation. J Electrocardiol6:131, 1973
24.
TheXamoterol In Severe Heart Failure Study Group. Xamoterol in severe heart failure . Lancet336:1, 1990
25.
PROMISE Study Research Group.Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med325:1468, 1991
26.
Mangin L., Swynghedauw B., Benis A., et al. Relationships between heart rate and heart rate variability: Study in conscious rats. J Cardiovasc Pharmacol32:601, 1998
27.
Wolk R., Kulakowski P., Ceremuzynski L.Nifedipine and captopril exert divergent effects on heart rate variability in patients with acute episodes of hypertension. J Hum Hypertens May; 10:327, 1996
28.
Marano G., Grigioni M., Tiburzi F., et al. Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits. J Cardiovasc Pharmacol28:513, 1996
29.
Cloarec-Blanchard L., Funck-Brentano C., Carayon A., et al. Rapid development of nitrate tolerance in healthy volunteers: Assessment using spectral analysis of short-term blood pressure and heart rate variability. J Cardiovasc Pharmacol24:266, 1994
30.
Tsutamoto T. , Bito K., Kinoshita M.Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. Am Heart J117:599, 1989
31.
Sugawara A. , Nakao K., Morii N., et al. Synthesis of atrial natriuretic polypeptide in human failing hearts. Evidence for altered processing of atrial natriuretic polypeptide precursor and augmented synthesis of beta-human ANP. J Clin Invest81:1962, 1988
32.
Alboni P., Paparella N., Cappato R., et al. Long-term effects of theophylline in atrial fibrillation with a slow ventricular response. Am J Cardiol15;72:1142, 1993
33.
Heinz G., Siostrzonek P., Kreiner G., et al. Improvement in left ventricular function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol69:489, 1993
34.
Van Gelder IC , Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol72:560, 1993
35.
Schumacher B., Luderitz B.Rate issues in atrial fibrillation: Consequences of tachycardia and therapy for rate control. Am J Cardiol82:29N, 1998
